YU9502A - Polimorfi torzemida - Google Patents

Polimorfi torzemida

Info

Publication number
YU9502A
YU9502A YU9502A YUP9502A YU9502A YU 9502 A YU9502 A YU 9502A YU 9502 A YU9502 A YU 9502A YU P9502 A YUP9502 A YU P9502A YU 9502 A YU9502 A YU 9502A
Authority
YU
Yugoslavia
Prior art keywords
torsemide
adduct
polymorphs
disclosed
methods
Prior art date
Application number
YU9502A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Judith Aronhime
David Leonov
Marko Kordova
Anchel Schwartz
Ben-Zion Dolitzky
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of YU9502A publication Critical patent/YU9502A/sh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
YU9502A 1999-08-11 2000-08-11 Polimorfi torzemida YU9502A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US18312700P 2000-02-17 2000-02-17
US21527300P 2000-06-30 2000-06-30

Publications (1)

Publication Number Publication Date
YU9502A true YU9502A (sh) 2005-06-10

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
YU9502A YU9502A (sh) 1999-08-11 2000-08-11 Polimorfi torzemida

Country Status (24)

Country Link
US (1) US6465496B1 (enExample)
EP (1) EP1207880A4 (enExample)
JP (1) JP2003527319A (enExample)
KR (1) KR20020025217A (enExample)
CN (1) CN1378448A (enExample)
AU (1) AU781461C (enExample)
BG (1) BG106400A (enExample)
CA (1) CA2379322A1 (enExample)
CZ (1) CZ2002404A3 (enExample)
DE (1) DE00957398T1 (enExample)
ES (1) ES2204354T1 (enExample)
HK (1) HK1046636A1 (enExample)
HR (1) HRP20020120A2 (enExample)
HU (1) HUP0204318A3 (enExample)
IL (1) IL148031A0 (enExample)
LT (1) LT5004B (enExample)
MX (1) MXPA02001369A (enExample)
NO (1) NO20020622L (enExample)
PL (1) PL354262A1 (enExample)
SI (1) SI20816A (enExample)
SK (1) SK1912002A3 (enExample)
TR (1) TR200200353T2 (enExample)
WO (1) WO2001010441A1 (enExample)
YU (1) YU9502A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK11632003A3 (sk) * 2000-02-17 2004-04-06 Teva Pharmaceutical Industries Ltd. Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (enExample) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) 1860-11-13 Improvement in fire-escapes
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
CA2403382A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
ES2204354T1 (es) 2004-05-01
US6465496B1 (en) 2002-10-15
HUP0204318A3 (en) 2005-03-29
CA2379322A1 (en) 2001-02-15
JP2003527319A (ja) 2003-09-16
NO20020622L (no) 2002-03-14
IL148031A0 (en) 2002-09-12
MXPA02001369A (es) 2005-08-26
HK1046636A1 (zh) 2003-01-24
PL354262A1 (en) 2003-12-29
NO20020622D0 (no) 2002-02-08
CZ2002404A3 (cs) 2002-06-12
EP1207880A1 (en) 2002-05-29
AU781461B2 (en) 2005-05-26
AU781461C (en) 2006-02-23
CN1378448A (zh) 2002-11-06
SK1912002A3 (en) 2002-07-02
EP1207880A4 (en) 2004-09-01
WO2001010441A1 (en) 2001-02-15
LT2002017A (en) 2002-11-25
HUP0204318A2 (en) 2003-05-28
DE00957398T1 (de) 2004-04-15
TR200200353T2 (tr) 2002-06-21
HRP20020120A2 (en) 2003-10-31
LT5004B (lt) 2003-03-25
SI20816A (sl) 2002-08-31
BG106400A (en) 2002-08-30
KR20020025217A (ko) 2002-04-03
AU6902600A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
YU9502A (sh) Polimorfi torzemida
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
AU5681800A (en) Quinoline derivatives as antibacterials
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
IL127296A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
IL112622A (en) Iminoalkylamino or aminoalkylideneamino camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them
CA2419314A1 (en) Preparation of risperidone
IL139861A (en) 17beta-AMINO-AND HYDROXYLAMINO -11 beta - ARYLSTEROID DERIVATIVES, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
AU5835400A (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and process for the preparation of the active substance
UA35607C2 (uk) Похідні оксазолідинонкарбонової кислоти, спосіб їх одержання, фармацевтична композиція і спосіб її одержання
JO2252B1 (en) Method for preparing pyridine derivatives
AU7270798A (en) Antithrombotic agents
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
MY120237A (en) Method for the synthesis of quinoline derivatives
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
HK1055058A2 (en) 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
AU7470098A (en) Antithrombotic agents
WO2001002340A3 (en) Novel aminoindanes
ZA979645B (en) Heterocyclic compounds, compositions and uses.
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
AU3814800A (en) Enantiomers of mercapto lactones and processes for their synthesis
ZA200005110B (en) Process for preparing intermediates.
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları
SE9803107D0 (sv) Novel Compunds